Form D · Biotechnology
EndoTheia, Inc.
Nashville, TN · CIK 0002037317
Offering snapshot reported Sep 18, 2024 · SEC filing
- Reported sold
- $500K Offering amount: $500K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 18, 2024 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-524306
Source: Form D, filed Sep 18, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joshua Gafford | Director, Executive |
| Sam Heleba | Director |
| S. Duke Herrell | Director, Executive |
| Brandon Hoffman | Director |
| Caleb Rucker | Director, Executive |
| Robert J. Webster | Director, Executive |
| Scott Webster | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1720 West End Ave. Suite 520
Nashville, TN, 37203
Nashville, TN, 37203